Medical Cannabis Research Group (MCRG) plans to take advantage of the underlying barrier of using a lawful source of cannabinoids (as described by UN Drug Treaties) for scientific research and medical uses.
By partnering with advanced researchers, MCRG will be in a better position to address technological barriers. The opportunities which now arise for MCRG due to the Australian Government’s new laws and opportune regulations will enable us the ability to explore and exploit various avenues of commercialisation.
Cannabis as a Potential Therapy for Multiple Sclerosis
Medical Cannabis Research Group entered into a sponsored research agreement with the Technion Research and Development Foundation Ltd (TRDF or Technion). The research is led by Professor Dedi Meri from the faculty of biology.
We are approaching this project in the spirit in which the Australian government has introduced new laws in relation to medical Cannabis research and drug development. Medical Cannabis research and the potential range of products that can be produced from cannabinoids leads us to believe there will be numerous opportunities for commercialization.
Given the ample number of opportunities that are emerging and now available to a company like the MCRG, returns are expected to be significant in the mid-to long-term. Most medical Cannabis products produced in Australia will be first to market and a substantial market share is anticipated.
In this work, we aim to elucidate the immunoregulatory properties of phytocannabinoids and terpenes in MS, as well as further investigate Cannabis’s mechanisms of action in these areas.
This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimise Cannabis treatment options and efforts toward the creation of personalised medicine for MS patients.
The objective of this study is to match effective Cannabis extracts and specific cannabinoid compositions that regulate/modulate immune function, specifically, autoimmunity in multiple sclerosis (MS) in order to optimise treatments for MS patients.
The basic premise of this research is that MS and other autoimmune conditions respond favourably to low doses of cannabinoids.
Our goal is to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. We intend to evaluate the immunomodulatory properties of specific cannabinoid extracts in in vivo rodent models of MS. This will enable us the ability to detect the most effective Cannabis extract(s) and cannabinoid profiles for regulating immunopathology in MS.